Anju Aggarwal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anju Aggarwal has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Moonis Akbar Faridi
Department of Pediatrics, Era’s Lucknow Medical College and Hospital, Lucknow 22600, India
2 shared publications Suman Rath
Department of Paediatrics, University College of Medical Sciences & Guru Teg Bahadur Hospital, Delhi, India
2 shared publicationsGhanshyam Das
Department of Pediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India
1 shared publicationManish Kumar
1 shared publicationShashiraj
Department of Paediatrics, University College of Medical Sciences & Guru Teg Bahadur Hospital, Delhi, India
1 shared publication
Latest Publications
- 1 September 2005
- Vol. 42 (9) , 913-8
Effect of carbamazepine on serum lipids and liver function tests.
We prospectively studied the effect of carbamazepine (CBZ) therapy on serum lipids and liver function tests in 28 patients and 28 age and sex matched controls. The mean age of patients was 8.29 years, duration of therapy with CBZ 10.3 months and dose of CBZ 13.1 mg/dL. The patients and controls were comparable in weight, height and BMI. Mean +/- SD of cholesterol 162 +/- 25.8 mg/dL in patients was significantly more than controls 131+/- 25.2 mg/dL. Mean LDL cholesterol and HDL cholesterol were also significantly raised in patients. Values of mean VLDL, triglycerides, ratio of LDL HDL, TC HDLC bilirubin and SGPT were not significantly different in two groups. Blood Levels of alkaline phosphatase were significantly more in patients compared to controls. The long term implications of these findings need to be studied.
- 1 September 2005
- Vol. 42 (9) , 913-8
Effect of carbamazepine on serum lipids and liver function tests.
We prospectively studied the effect of carbamazepine (CBZ) therapy on serum lipids and liver function tests in 28 patients and 28 age and sex matched controls. The mean age of patients was 8.29 years, duration of therapy with CBZ 10.3 months and dose of CBZ 13.1 mg/dL. The patients and controls were comparable in weight, height and BMI. Mean +/- SD of cholesterol 162 +/- 25.8 mg/dL in patients was significantly more than controls 131+/- 25.2 mg/dL. Mean LDL cholesterol and HDL cholesterol were also significantly raised in patients. Values of mean VLDL, triglycerides, ratio of LDL HDL, TC HDLC bilirubin and SGPT were not significantly different in two groups. Blood Levels of alkaline phosphatase were significantly more in patients compared to controls. The long term implications of these findings need to be studied.
- Open Access
- 1 April 2005
- Published by Oxford University Press (OUP) in Journal of Tropical Pediatrics
- Vol. 51 (2) , 120-121
Plasmodium vivax Malaria Presenting with Severe Thrombocytopenia
Haematological changes are common in malaria. Thrombocytopenia is a common finding in falciparum infection but rare in Plasmodium vivax. We report a case of 7-year-old male patient presenting with fever, petechial rash, and platelet counts of 6 × 109/l due to Plasmodium vivax malaria.
- 1 April 2005
- Published by Oxford University Press (OUP) in Journal of Tropical Pediatrics
- Vol. 51 (2) , 120-121
Open AccessPlasmodium vivax Malaria Presenting with Severe Thrombocytopenia
Haematological changes are common in malaria. Thrombocytopenia is a common finding in falciparum infection but rare in Plasmodium vivax. We report a case of 7-year-old male patient presenting with fever, petechial rash, and platelet counts of 6 × 109/l due to Plasmodium vivax malaria.
- 1 May 2004
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 71 (5) , 413-415
Cefpodoxime — utility in respiratory tract infections and typhoid fever
Cefpodoxime is a oral third generation cephalosporin active against most of gram positive and gram negative bacteria except Pseudomonas, B. fragilis and Entrococcous. Clinical studies have confirmed efficacy of cefpodoxime in acute otitis media, sinusitis and tosillopharyngitis. Twice daily administration and safety profile increases compliance and decreases failure rate. It has a role as switch over therapy from intravenous ceftriaxone in serious respiratory tract infections (RTIs). In areas where common respiratory pathogens show decreased sensitivity to penicillins and macrolides cefpodoxime can be used as empirical first line therapy in respiratory tract infections. It seems to be a promising molecule in pediatric typhoid fever because of its excellent activity against Salmonella species but clinical trials are limited.
- 1 May 2004
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 71 (5) , 413-415
Cefpodoxime — utility in respiratory tract infections and typhoid fever
Cefpodoxime is a oral third generation cephalosporin active against most of gram positive and gram negative bacteria except Pseudomonas, B. fragilis and Entrococcous. Clinical studies have confirmed efficacy of cefpodoxime in acute otitis media, sinusitis and tosillopharyngitis. Twice daily administration and safety profile increases compliance and decreases failure rate. It has a role as switch over therapy from intravenous ceftriaxone in serious respiratory tract infections (RTIs). In areas where common respiratory pathogens show decreased sensitivity to penicillins and macrolides cefpodoxime can be used as empirical first line therapy in respiratory tract infections. It seems to be a promising molecule in pediatric typhoid fever because of its excellent activity against Salmonella species but clinical trials are limited.
- 1 March 2003
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 70 (3) , 265-267
Dizygotic twins with myelomeningocele.
- 1 March 2003
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 70 (3) , 265-267
Dizygotic twins with myelomeningocele.